Here are 1-3 brief analogies for Sophia Genetics:

• Palantir for genomic and medical data analysis

• A Snowflake for precision medicine data platforms

• A DeepMind for medical diagnostics

• SOPHiA DDM™ Platform: An AI-powered software-as-a-service (SaaS) platform that analyzes complex genomic and radiomic data to assist clinicians in diagnosing and treating diseases like cancer and hereditary disorders.
• Genomic Analysis Services: Services leveraging the SOPHiA DDM™ Platform for interpreting genomic sequencing data to identify mutations and biomarkers relevant to various conditions, including oncology and rare diseases.
• Radiomic Analysis Services: Services utilizing the SOPHiA DDM™ Platform to extract and interpret quantifiable features from medical images, providing insights for advanced diagnostics and personalized treatment planning.
• Data-Driven Medicine Network: A global collaborative network connecting healthcare institutions to share and analyze anonymized patient data, driving research, discovery, and improved clinical outcomes.

Sophia Genetics (symbol: SOPH) primarily operates on a Business-to-Business (B2B) model, providing its Sophia DDM™ platform and related services to various healthcare institutions.

Sophia Genetics does not publicly disclose the names of specific individual "major customer companies" that account for a significant portion of its revenue. This is a common practice for SaaS platforms serving a broad and diversified customer base within the healthcare sector, often due to confidentiality agreements and the fact that no single customer represents a material percentage of total revenue. Instead, the company derives its revenue from a global network of hundreds of healthcare institutions.

The companies and institutions Sophia Genetics serves can be broadly categorized as follows:

• Hospitals and Academic Medical Centers: These institutions utilize Sophia Genetics' platform for advanced genomic and radiomic data analysis to support clinical decision-making, particularly in areas like oncology, rare diseases, and inherited conditions.
• Commercial Diagnostic Laboratories: These laboratories integrate Sophia DDM™ to enhance their capabilities in processing, interpreting, and reporting complex genomic and imaging data for patient diagnostics, helping them offer cutting-edge testing services.
• Biopharmaceutical Companies: Sophia Genetics collaborates with biopharmaceutical firms, leveraging its data analysis solutions to support research and development, biomarker discovery, clinical trials, and companion diagnostics initiatives.

• Amazon.com, Inc. (AMZN)

Jurgi Camblong Co-Founder, Chief Executive Officer and Director
Dr. Jurgi Camblong is a visionary entrepreneur and molecular biologist who co-founded SOPHiA GENETICS in 2011 with Dr. Pierre Hutter and Prof. Lars Steinmetz. He holds a PhD in life sciences and an EMBA in management of technology. Dr. Camblong successfully led the company's development, including its IPO in July 2021. Before founding SOPHiA GENETICS, he served as CEO of Gene Predictis. He was recognized by EY as Emergent Entrepreneur of the Year in 2017 and was a member of the Advisory Council on Digital Transformation to the Swiss Government.

George Cardoza Executive Vice President and Chief Financial Officer
George Cardoza joined SOPHiA GENETICS as CFO in November 2024. He brings over 30 years of experience in precision medicine and clinical diagnostics. Prior to this role, Mr. Cardoza served as the Chief Financial Officer and Head of Service Delivery for Biocartis. He was also the Chief Executive Officer at Accuragen and spent over twelve years with NeoGenomics in various leadership capacities, including Chief Financial Officer, President of Pharma Services, and Chief Operating Officer. His career also includes more than fourteen years at Quest Diagnostics in various roles, such as Controller of the Central Region.

Ross Muken President
Ross Muken was promoted to President of SOPHiA GENETICS in November 2024. He joined the company in February 2021 as CFO and was appointed CFO & COO in March 2023. Mr. Muken is a seasoned executive with over 20 years of experience across life sciences, health technology, medical devices, and pharma services. Before SOPHiA GENETICS, he was CFO & COO of Click Therapeutics, where he negotiated significant deals, including a $500 million agreement with Boehringer Ingelheim and a $300 million deal with Otsuka. He also held roles as Partner, Senior Managing Director, and head of healthcare services & technology equity research at Evercore/ISI Group, and as Senior Managing Director at Deutsche Bank Securities. He played a key role in taking SOPHiA GENETICS public through an IPO in 2021.

Philippe Menu Executive Vice President, Chief Medical Officer and Chief Product Officer
Dr. Philippe Menu, M.D., Ph.D., M.B.A., joined SOPHiA GENETICS in February 2020 as Chief Medical Officer and was appointed Chief Product Officer and Chief Medical Officer in March 2023. He brings a unique blend of medical expertise from clinical medicine, molecular biology research, and business management consulting. Prior to SOPHiA GENETICS, Dr. Menu spent 8 years at McKinsey & Company, where he advised numerous clients in the BioPharma sector on innovative therapies and diagnostics, particularly in oncology and rare diseases.

Abhimanyu (Abhi) Verma Senior Vice President and Chief Technology Officer
Abhimanyu (Abhi) Verma joined SOPHiA GENETICS in February 2022 as Senior Vice President and Chief Technology Officer. He is a healthcare technology leader with over 17 years of life sciences industry experience. His expertise lies in developing capabilities and leading multifunctional organizations to create and accelerate solutions that impact patients across various therapeutic areas and functions within the pharmaceutical value chain.

The increasing and aggressive entry of major cloud providers and tech giants (such as Google Cloud, Amazon Web Services, and Microsoft Azure) into the healthcare AI and genomics data analysis space represents a clear emerging threat. These companies are building robust platforms, AI/ML services, and data infrastructure that could directly compete with Sophia Genetics' core offerings. Their vast resources, established enterprise relationships, and ability to bundle services, potentially enabling healthcare institutions to build in-house alternatives more easily and cost-effectively or to utilize competing integrated solutions, pose a significant long-term disruptive threat.

Sophia Genetics (SOPH) operates primarily in the fields of genomics and precision medicine through its AI-powered SOPHiA DDM™ platform, which is used for analyzing complex genomic and multimodal data in oncology and rare disorders.

The company estimates its total addressable market (TAM) to be approximately $40 billion, covering both clinical diagnostics and biopharma applications globally.

Beyond the company's own estimate, the broader addressable markets for Sophia Genetics' main products and services are significant:

• The global genomics market was valued at approximately USD 32.65 billion in 2023 and is projected to reach USD 94.86 billion by 2030, growing at a Compound Annual Growth Rate (CAGR) of 16.5%. Other estimates place the global genomics market at around USD 38.4 billion in 2024, projected to grow to USD 113.3 billion by 2033 (CAGR of 12.77%). North America held the largest share of the global genomics market, accounting for 42.65% in 2024, with the U.S. alone capturing over 80% of that regional market.
• The global precision medicine market was estimated at USD 119.03 billion in 2025 and is predicted to increase to approximately USD 470.53 billion by 2034, expanding at a CAGR of 16.50%. Another report indicates the global precision medicine market reached USD 82.1 billion in 2024 and is expected to reach USD 179.4 billion by 2033, with a CAGR of 8.63%. North America is a dominant region in the global precision medicine market.
• The global AI platform market, which is relevant given Sophia Genetics' AI-driven platform, was valued at USD 11.3 billion in 2023 and is poised to grow to USD 97.39 billion by 2032 (CAGR of 23.9%). Another source estimated the global AI platform market at USD 14.21 billion in 2024, projected to reach USD 251.01 billion by 2033 at a CAGR of 38.1%. Within this market, the healthcare and life sciences segment is expected to experience the fastest growth, at a CAGR of 40.8% from 2025 to 2033. North America dominated the global AI platform market with a 26.4% revenue share in 2024.

Expected Drivers of Future Revenue Growth for Sophia Genetics (SOPH)

Sophia Genetics (SOPH) is anticipated to drive future revenue growth over the next 2-3 years through several key strategies:

1. Geographical Expansion: The company is actively pursuing a multi-faceted expansion strategy to broaden its market reach, particularly in North America, Europe, and the Asia-Pacific region. This involves strengthening its presence in new and emerging markets where the adoption of precision medicine is increasing, leveraging its established network of hospitals and laboratories.

2. Customer Acquisition and Expansion: Sophia Genetics aims to expand its client base by demonstrating the cost-effectiveness and clinical utility of its AI-powered analytics platform. The company is focused on converting new customers into revenue-generating accounts and growing revenue from existing customers through a "land-and-expand" strategy. Recent reports indicate the signing of record numbers of new customers and a significant increase in the average contract value of new deals.

3. Launch and Growth of New Products and Applications: Sophia Genetics is diversifying its offerings by broadening its analytical capabilities beyond genomics and radiomics, exploring new data modalities, and integrating them into its SOPHiA DDM platform. Key growth is expected from new applications in specific disease areas like oncology and rare diseases, including the successful adoption of liquid biopsy solutions such as MSK-ACCESS®, which carries higher-than-average selling prices. Additionally, the company has launched AI-powered Digital Twins to enhance decision-making in oncology.

4. Strategic Partnerships, particularly with Biopharma: Collaborations with pharmaceutical companies, research institutions, and technology providers are crucial for Sophia Genetics to co-develop solutions, access new distribution channels, and enhance drug development and clinical trials. A notable partnership with AstraZeneca, focusing on AI breast cancer research and the expansion of liquid biopsy testing, is expected to drive future recurring revenues.

Share Issuance

• Sophia Genetics completed its Initial Public Offering (IPO) on July 27, 2021, issuing 13,000,000 ordinary shares at $18 per share, which generated gross proceeds of $234 million.
• Concurrently with the IPO, the company issued and sold 1,111,111 ordinary shares to an affiliate of GE Healthcare through a private placement, resulting in gross proceeds of $20 million.
• Underwriters were granted an option to purchase up to 1,950,000 additional ordinary shares at the initial public offering price.

Inbound Investments

• In October 2020, Sophia Genetics closed a $110 million Series F financing round, led by aMoon and Hitachi Ventures.
• An affiliate of GE Healthcare made a $20 million investment in Sophia Genetics through a private placement of ordinary shares in July 2021, concurrent with the company's IPO.

Outbound Investments

• No significant dollar amount outbound investments (e.g., acquisitions or equity investments in other companies) have been reported by Sophia Genetics within the last 3-5 years.

Capital Expenditures

• Sophia Genetics reported capital expenditures of -$293,000 over the last 12 months as of November 7, 2025.
• Since its inception in 2011, the company has invested over $400 million in building its AI capabilities and the SOPHiA DDM™ Platform, including recruiting over 200 data scientists and engineers.
• Proceeds from the 2021 IPO were designated for working capital and corporate activities such as research and development, expanding sales and marketing, and developing customer relationships.